Barclays Reiterates Overweight Rating on Protagonist Therapeutics, Inc. (PTGX)

Market Context

Protagonist Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $130.81 with a market capitalization of $5.8B.

Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Protagonist Therapeutics, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Protagonist Therapeutics, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 14, 2026	Barclays	Overweight	N/A
Jul 07, 2026	Truist Securities	Buy	N/A
May 06, 2026	Wedbush	Outperform	N/A
May 06, 2026	Citizens	Market Outperform	N/A
Apr 15, 2026	Truist Securities	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View PTGX Stock Page